Skip to main content

Peer Review reports

From: An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations

Original Submission
13 Jan 2021 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
8 Feb 2021 Reviewed Reviewer Report
10 Mar 2021 Reviewed Reviewer Report
4 May 2021 Author responded Author comments - Keunchil Park
Resubmission - Version 3
4 May 2021 Submitted Manuscript version 3
11 May 2021 Reviewed Reviewer Report
15 May 2021 Reviewed Reviewer Report - alessandro russo
27 May 2021 Author responded Author comments - Keunchil Park
Resubmission - Version 4
27 May 2021 Submitted Manuscript version 4
Publishing
28 May 2021 Editorially accepted
12 Jul 2021 Article published 10.1186/s12885-021-08445-9

You can find further information about peer review here.

Back to article page